Latest news


Mandatory notification of trade

Posted on Jul 6, 2015

Lysaker, June 30 2015 – The primary insider and Chief Business Development Officer, Gaël L’Hévéder, has purchased a total of 10 000 shares. 8 000 shares are purchased at a price of NOK 6.00 per share and 2 000 shares at a price of NOK 5.45 per share. After this the primary insider, Gaël L’Hévéder, holds […]

Mandatory notification of trade

Posted on Jun 8, 2015

Lysaker, June 8 2015 – The primary insider and CEO, Per Walday, has purchased 3 500 shares at a price of NOK 6.62 per share. After this the primary insider, Per Walday, holds a total of 44 019 shares and 126 000 unexercised options in the company, corresponding to 80 000 unexercised options at a […]

Update on the ENHANCE study

Posted on Jun 3, 2015

Lysaker, June 3 2015 – PCI Biotech reported today that, following a strategic review of the company’s assets, it has decided to stop the ENHANCE study and focus the company’s resources towards the clinical bile duct cancer study and the promising immunotherapy opportunities offered by the PCI technology. This decision was based on both strategic […]